Belarus Bans Sales of 47 E-cigarette Products for Health Concerns

Regulations by 2FIRSTS.ai
Mar.05.2024
Belarus Bans Sales of 47 E-cigarette Products for Health Concerns
Belarus bans sale of 47 e-cigarettes due to health risks, including nicotine overdose and lack of safety information.

Recently, according to the Truth Report of the Communist Youth League, the State Standardization Bureau of Belarus has banned the sale of 47 types of e-cigarettes in the market. Media reports cited the information from the Gomel Branch of the State Standardization Bureau of Belarus, stating that after regulatory measures in January and February of this year, it was found that some e-cigarettes being sold in the Gomel market did not meet legislative requirements.

 

According to a statement released by the news department, the ban on the 47 e-cigarette series is due to their potential and evident health risks.

 

The e-cigarettes with problems include e-liquids that contain excessive nicotine (exceeding the limit of 20mg per milliliter) and e-liquids that have five times the legal capacity (exceeding the 2ml limit). In addition, some e-cigarette products lack expiration date information, usage restriction warnings, disease contraindications, and information on potential illnesses that may be caused. Some e-cigarette products even fail to provide relevant documents on product compliance and safety. "Using these e-cigarettes will directly threaten the health of consumers," the Belarusian State Standardization Agency emphasized.

 

The non-compliant products have been taken off the shelves and administrative penalties have been imposed on the sellers.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JTI Plans New Factory in Romania, Set for Completion in 2027
JTI Plans New Factory in Romania, Set for Completion in 2027
JTI has announced plans to build a new factory in Ștefăneștii de Jos to replace its current Bucharest site, which faces space constraints. The project is expected to be completed in 2027, with ground works starting soon. The company highlighted ongoing efforts to expand capacity and modernize its Romanian operations.
Nov.28
EPO Invalidates Philip Morris Heated Tobacco Patent After Imperial Brands Challenge
EPO Invalidates Philip Morris Heated Tobacco Patent After Imperial Brands Challenge
The European Patent Office invalidated Philip Morris International’s heated tobacco patent, ruling it lacked inventiveness after a challenge by Imperial Brands’ subsidiary Fontem Ventures BV.
Oct.11 by 2FIRSTS.ai
Teen Nicotine Use Surges in Pakistan as Flavoured Vapes Spread Rapidly
Teen Nicotine Use Surges in Pakistan as Flavoured Vapes Spread Rapidly
Pakistan is experiencing a sharp rise in nicotine use among teenagers, driven by widespread availability of flavoured vapes and e-cigarettes. Cheap, sweet-flavoured devices are easily accessible in major cities, and weak enforcement of age limits has enabled young users to adopt vaping at alarming rates. Activists warn that industry marketing falsely portrays e-cigarettes as “safer,” putting youth at risk of long-term addiction and serious health effects.
Nov.14 by 2FIRSTS.ai
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.
Oct.21
BAT expands facial age-estimation checks: over 600 stores covered in Europe, targeting 1,000 by year-end
BAT expands facial age-estimation checks: over 600 stores covered in Europe, targeting 1,000 by year-end
BAT has partnered with the Channel Islands Co-operative Society and Yoti to pilot facial age estimation in 10 Coop stores across Jersey. Customers scan a QR code and take a selfie; the system instantly deletes the image and returns only a yes/no against a minimum age threshold (set at 20) for the pilot. BAT already uses Yoti in 600+ stores across Europe and plans to reach 1,000 by year-end.
Oct.22 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21